Tillkännagivande • Sep 09

UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome

UCB announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to CIMZIA (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant women who have antiphospholipid syndrome (APS) and are positive for lupus anticoagulant (LA). These patients were considered at risk due to prior obstetric and blood clotting (thrombotic) events. The designation is supported by preliminary clinical evidence from the IMPACT study, and recognizes the potential of CIMZIA to address a significant unmet medical need in an area where there are currently no FDA-approved therapies for the prevention of adverse pregnancy outcomes in patients with APS. A BTD is granted to medicines intended to treat a serious or life-threatening condition when preliminary clinical evidence indicates the therapy may demonstrate substantial improvement over available treatments on one or more clinically significant endpoints. The designation is designed to facilitate development and expedite the FDA review of promising new therapies. APS is a rare autoimmune disorder associated with increased risk of blood clots and serious pregnancy complications, including recurrent pregnancy loss in the first trimester, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth, and stillbirth. Despite the significant burden of the condition, patients are typically managed with low-dose aspirin and heparin, highlighting a substantial unmet medical need. Results from the IMPACT study demonstrated the potential of CIMZIA to prevent adverse pregnancy outcomes in women with APS considered high risk due to LA positivity and prior obstetric or thrombotic manifestations of the disease. The findings add to growing evidence implicating tumor necrosis factor (TNF)-mediated inflammation in APS-related pregnancy complications. The designation builds on the FDA's recent Orphan Drug Designation for CIMZIA for the prevention of placenta-mediated adverse pregnancy outcomes in pregnant patients with APS. CIMZIA is not currently approved in pregnant women with APS, and the safety and efficacy have not been established for this use. Antiphospholipid syndrome (APS) is a rare and serious autoimmune condition that mainly affects women of childbearing age (WoCBA), characterized by the presence of antiphospholipid antibodies, which can cause repeated blood clots in arteries and veins. The condition is associated with serious pregnancy complications, including recurrent pregnancy loss in the first trimester, pre-eclampsia, placental insufficiency, fetal growth restriction, preterm birth, stillbirth, and a range of serious placenta-mediated adverse pregnancy outcomes. Current standard-of-care treatment typically includes low-dose aspirin and heparin during pregnancy; however, no therapies are currently approved specifically for the prevention of adverse pregnancy outcomes in this patient population. IMPACT (IMProve Pregnancy in APS with Certolizumab Therapy) was an investigator-sponsored study evaluating certolizumab pegol in pregnant women with APS at high risk of adverse pregnancy outcomes. Published results demonstrated the potential of certolizumab pegol to prevent adverse pregnancy outcomes in this high-risk population. Breakthrough Therapy Designation (BTD) is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. The designation is granted when preliminary clinical evidence indicates that a therapy may demonstrate substantial improvement over available treatment options on one or more clinically significant endpoints. BTD provides opportunities for more intensive FDA guidance and organizational commitment to support efficient development and review, and is not a label indication approval. Orphan Drug Designation is granted by the FDA to medicines intended for the treatment, prevention, or diagnosis of rare diseases or conditions affecting fewer than 200,000 people in the United States. The designation is designed to encourage the development of therapies for rare diseases and may provide incentives to sponsors, including development support and certain regulatory and commercial benefits. The designation does not constitute marketing approval or determine a medicine's safety or efficacy. CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy; Treatment of adults with moderately to severely active rheumatoid arthritis (RA); Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older; Treatment of adult patients with active psoriatic arthritis (PsA); Treatment of adults with active ankylosing spondylitis (AS); Treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation; Treatment of adults with moderate-to-severe plaque psoriasis (PSO) who are candidates for systemic therapy or phototherapy. Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member. CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria. Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue CIMZIA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before CIMZIA use and during therapy. Initiate treatment for latent TB prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease.

Pharmaceuticals Tillväxt i branschen	5.95%
Intäkternas tillväxttakt	7.88%
Avkastning på eget kapital	18.83%
Nettomarginal	25.74%
Senaste uppdateringen av resultatet	30 Jun 2026

Datum	Intäkter	Intäkter	G+A Kostnader	FoU-kostnader
30 Jun 26	8,524	2,194	2,839	1,875
31 Mar 26	8,133	1,876	2,794	1,849
31 Dec 25	7,741	1,558	2,749	1,822
30 Sep 25	7,295	1,445	2,654	1,837
30 Jun 25	6,848	1,332	2,559	1,852
31 Mar 25	6,500	1,199	2,453	1,817
31 Dec 24	6,152	1,065	2,347	1,781
30 Sep 24	5,803	653	2,190	1,721
30 Jun 24	5,454	240	2,033	1,660
31 Mar 24	5,318	292	1,929	1,645
31 Dec 23	5,182	343	1,824	1,630
30 Jun 23	5,111	332	1,726	1,631
31 Mar 23	5,279	376	1,720	1,651
31 Dec 22	5,447	420	1,714	1,670
30 Jun 22	5,854	887	1,695	1,674
31 Mar 22	5,816	971	1,625	1,652
31 Dec 21	5,777	1,055	1,554	1,629
30 Sep 21	5,647	996	1,506	1,631
30 Jun 21	5,517	936	1,458	1,633
31 Mar 21	5,432	834	1,438	1,601
31 Dec 20	5,347	732	1,417	1,569
30 Jun 20	5,198	743	1,368	1,393
31 Mar 20	5,056	767	1,336	1,333
31 Dec 19	4,913	790	1,303	1,272
30 Jun 19	4,686	652	1,212	1,229
31 Mar 19	4,659	722	1,178	1,195
31 Dec 18	4,632	792	1,144	1,161
30 Jun 18	4,569	872	1,105	1,083
31 Mar 18	4,522	812	1,119	1,070
31 Dec 17	4,474	752	1,132	1,057
30 Sep 17	4,400	708	1,138	1,047
30 Jun 17	4,325	664	1,144	1,036
31 Mar 17	4,236	604	1,133	1,028
31 Dec 16	4,147	543	1,122	1,020
30 Sep 16	4,051	439	1,111	1,022
30 Jun 16	3,955	334	1,099	1,023
31 Mar 16	3,916	299	1,098	1,030
31 Dec 15	3,876	264	1,096	1,037
30 Sep 15	3,773	266	1,069	999

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/09/13 06:25
Aktiekurs vid dagens slut	2026/09/11 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
Charles Pitman	Barclays
Brian Bourdot	Barclays
Kerry Holford	Berenberg

UCB Tidigare resultatutveckling

Tidigare kriterier kontrolleras 5/6

Viktig information

Senaste uppdateringar av tidigare prestationer

UCB SA to Report First Half, 2025 Results on Jul 31, 2025

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

Recent updates

UCB Receives U.S. FDA Breakthrough Therapy Designation For CIMZIA (Certolizumab Pegol) In Pregnant Women With Antiphospholipid Syndrome

UCB Publishes Results Of Post Hoc Data Analysis Of Fintepla In Patients With Lennox-Gastaut Syndrome

UCB Publishes Data Demonstrating Positive Impact Of Kygevvi In Patients With Thymidine Kinase 2 Deficiency

UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026

UCB SA (ENXTBR:UCB) completed the acquisition of Neurona Therapeutics, Inc.

Ucb Announces Superior Efficacy of Bimzelx over Skyrizi in Psoriatic Arthritis

UCB SA (ENXTBR:UCB) signed a definitive agreement to acquire Candid Therapeutics, Inc. from Vida Ventures Advisors, LLC and Two River Group Holdings, LLC for $2.2 billion.

UCB SA (ENXTBR:UCB) signed a definitive agreement to acquire Neurona Therapeutics, Inc. for approximately $1.2 billion.

UCB Presents New Data Demonstrating Quality-of-Life Impacts for Epilepsy Patients and Caregivers at AAN 2026 Meeting

UCB SA Presents New Clinical Data from Its Generalized Myasthenia Gravis Portfolio At the American Academy of Neurology Meeting

UCB Announces New BIMZELX (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

UCB Announces Bimzelx Demonstrates Superiority Over Skyrizi In Active Psoriatic Arthritis

UCB Presents Positive Results from GEMZ Phase 3 Study at AES Showing Fenfluramine Significantly Reduced Countable Motor Seizures in CDKL5 Deficiency Disorder

UCB to Present 21 Abstracts at American Epilepsy Society Annual Meeting

U.S. FDA Approves KYGEVVI®? (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 Deficiency (TK2d)

UCB Announces Three-Year Data from the BE HEARD Trials for BIMZELX®

UCB SA to Unveil New Data for RYSTIGGO (rozanolixizumab-noli) and ZILBRYSQ for gMG

UCB Announces New Three-Year Data from Phase 3 Trials, and Their Open-Label Extensions

UCB Announces Results from Multicenter Retrospective Chart Review Study of Investigational Pyrimidine Nucleoside and/or nucleotide Therapy in Patients with Thymidine Kinase 2 Deficiency

UCB Announces Three- and Four-Year Data from Across the Open-Label Extension Phase 3 Trials for BIMZELX®? in Moderate-To-Severe Plaque Psoriasis

UCB Announces Three-Year Data from the BE HEARD Trials for BIMZELX

UCB Announces Results from the Rheum for Improvement Survey

UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder

UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus

UCB SA to Report First Half, 2025 Results on Jul 31, 2025

UCB Presents Latest Research Across Leading Neurology Portfolio At American Academy of Neurology (AAN) Meeting

UCB SA Announces Step Down of Fiona Du Monceau from the Board of Directors

UCB Announces Positive Data from Studies Inviding Its Investigational Therapy, Doxecitine and Doxribtimine

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet Syndrome

UCB SA Proposes Dividend

UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB SA, Annual General Meeting, Apr 27, 2023

Fördelning av intäkter och kostnader

Resultat- och intäktshistorik

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Avkastning på eget kapital

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

Företagsanalys och finansiella data Status

Datakällor

Analysmodell och snöflinga

Industri- och sektormått

Källor för analytiker